Key facts
- AMPED PCR’s last known valuation is $2.9M (Dec 2024).
- It has raised $750K; the latest was Grant ($130K) in May 2025.
- Notable investors include SFC Capital, UK Research and Innovation, Development Bank of Wales, Aberystwyth AberInnovation, Nurture Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for AMPED PCR
- ·The full record, as it builds
Funding rounds
No funding rounds for AMPED PCR are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AMPED PCR
Developer of polymerase chain reaction (PCR) technology designed to make molecular diagnostics faster and more accessible outside traditional laboratories. The company focuses on developing innovative PCR reagents, kits, and protocols to enhance the sensitivity, speed, and reliability of DNA amplification for research, diagnostics, and applied sciences, enabling clinical laboratories and commercial research organizations to accelerate scientific discovery and improve diagnostic outcomes..
- Sector
- Business Products and Services (B2B)
- HQ
- Aberystwyth, United Kingdom
- Founded
- 2022
- Employees
- 2
- Website
- ampedpcr.co.uk/
- Ownership
- Privately Held (backing)
AMPED PCR doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AMPED PCR shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AMPED PCR in its N-PORT filings yet. We sweep new filings monthly.